Erkan Batti
Research Subjects
Erkan Batti has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bernard O Emuze
Emergency Medicine, St. James School of Medicine, Fort Worth, USA
1 shared publication Elizabeth O Amos-Arowoshegbe
Department of Medicine, Windsor University School of Medicine, Basseterre, KNA
1 shared publication- Kuchalambal Agadi
Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL 60640, USA
1 shared publication - Manoj Reddy Somagutta
Department of Medicine and Research, Avalon University School of Medicine, Willemstad, CUW
1 shared publication - Maria Kezia Lourdes Pormento
Medicine, Ateneo de Manila School of Medicine and Public Health, Quezon City, PHL
1 shared publication - Molly S. Jain
Medicine, Saint James School of Medicine, Park Ridge, USA
1 shared publication
Latest Publications
- Open Access
- 3 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
Diabetic ketoacidosis (DKA) is an acute and significant life-threatening complication of diabetes. The association of sodium-glucose cotransporter-2 inhibitors (SGLT2i) with euglycemic diabetic ketoacidosis (EDKA) has been well reported. This literature review was conducted to understand the mechanism of EDKA and identify the potential risk factors and precipitants for patients taking SGLT2i. After reviewing the published literature between 2010 and 2020, 32 articles are included in the final review. The underlying mechanism is mainly enhanced lipolysis and ketone body reabsorption. SGLT2i also stimulates pancreatic alpha cells and inhibits beta cells, causing an imbalance in glucagon/insulin levels, further contributing to lipolysis and ketogenesis. Most patients were diagnosed with blood glucose less than 200 mg/dL, blood pH <7.3, increased anion gap, increased blood, or urine ketones. Perioperative fasting, pancreatic etiology, low carbohydrate or ketogenic diet, obesity, and malignancy are identified precipitants in this review. As normoglycemia can conceal the underlying acidosis, physicians should be cognizant of the EDKA diagnosis and initiate prompt treatment. Patient education on risk factors and triggers is recommended to avoid future events.
- 3 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
Open AccessEuglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
Diabetic ketoacidosis (DKA) is an acute and significant life-threatening complication of diabetes. The association of sodium-glucose cotransporter-2 inhibitors (SGLT2i) with euglycemic diabetic ketoacidosis (EDKA) has been well reported. This literature review was conducted to understand the mechanism of EDKA and identify the potential risk factors and precipitants for patients taking SGLT2i. After reviewing the published literature between 2010 and 2020, 32 articles are included in the final review. The underlying mechanism is mainly enhanced lipolysis and ketone body reabsorption. SGLT2i also stimulates pancreatic alpha cells and inhibits beta cells, causing an imbalance in glucagon/insulin levels, further contributing to lipolysis and ketogenesis. Most patients were diagnosed with blood glucose less than 200 mg/dL, blood pH <7.3, increased anion gap, increased blood, or urine ketones. Perioperative fasting, pancreatic etiology, low carbohydrate or ketogenic diet, obesity, and malignancy are identified precipitants in this review. As normoglycemia can conceal the underlying acidosis, physicians should be cognizant of the EDKA diagnosis and initiate prompt treatment. Patient education on risk factors and triggers is recommended to avoid future events.